Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference F. Roila, J. Herrstedt, M. Aapro, R. J. Gralla, L. H. Einhorn, E. Ballatori, E. Bria, R. A. ClarkSnow, B. T. Espersen, P. Feyer, S. M. Grunberg, P. J. Hesketh, K. Jordan, M. G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B. L. Rapoport, C. Rittenberg, M. Saito, M. Tonato & D. Warr On behalf of the ESMO/MASCC Guidelines Working Group* Department of Medical Oncology, S. Maria University Hospital, Terni, Italy; Odense University Hospital, Odense, Denmark; Institut Multidisciplinaire d’Oncologie, Genolier, Switzerland; North Shore, LIJ Health System, Hofstra University School of Medicine, Lake Success, USA; Walther Cancer Institute, Indianapolis, USA; Medical Statistician, Spinetoli, Italy; Regina Elena National Cancer Institute, Rome, Italy; Lawrence Memorial Hospital, Lawrence, USA; Aarhus University Hospital, Aarhus, Denmark; Clinic of Radiotherapy, Vivantes Clinics, Berlin-Neukoelln, Berlin, Germany; University of Vermont, Burlington, USA; Lahey Clinic, Burlington, USA; University of Halle, Halle, Germany; Memorial Sloan-Kettering Cancer Center, New York, USA; Radiation Oncology Centre, S. Maria Hospital, Terni, Italy; School of Nursing, University of Manchester, Coupland, Manchester, UK; University of Rochester Cancer Center, Rochester, USA; Cancer Council Australia, Sidney, Australia; Medical Oncology Centre of Rosebank, Johannesburg, South Africa; Rittenberg Oncology Consulting, Metairie, USA; Juntendo University Hospital, Tokyo, Japan; Umbria Regional Cancer Network Perugia, Italy; Princess Margaret Hospital, University of Toronto, Canada